Efficacy, safety, and tolerability of IVIG-SN in patients with primary immunodeficiency
Abstract
Background: IVIG-SN is a modern intravenous immunoglobulin with multiple pathogen elimination steps. This clinical trial in patients with primary immunodeficiency (PID) was designed to evaluate the safety, efficacy, and tolerability of this product in adults and children.
Methods: Forty-four patients with PID were treated with IVIG-SN for 12 months. IgG trough levels and pharmacokinetics of IVIG-SN were evaluated as well as efficacy and safety according to standard FDA guidelines.
Results: Overall, a total of 572 IVIG-SN infusions were administered according to either a 21- or a 28-day schedule. IgG trough levels during the treatment period ranged from 823.00 to 902.77 mg/dL, respectively, and half-life in serum of the administered IgG was 43.45 ± 30.25 days. There were no deaths and no adverse events leading to withdrawal from the study. Of all infusions administered, only 137 (24%) were temporally associated with an adverse event (AE). The upper bound for the 95% CI for the frequency of infusions temporally associated with an AE was 29.2%. Drug-related AEs were predominantly mild, and there were no acute serious bacterial infections during the study. Efficacy was also demonstrated by low rates of missed work, school, or daycare days (mean 2.6 days); unscheduled visits to physicians (mean 1.7); and therapeutic antibiotic use (mean 15 days).
Conclusion: IVIG-SN is effective in preventing infections and is safe and well tolerated.
Statement of novelty: This efficacy and toxicity trial was conducted using a new IVIG preparation.
Formats available
You can view the full content in the following formats:
REFERENCES
Berger M. Felbogamma® 5% DIF® Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency disease patients of Flebogamma 5% DIF®, the next generation of Flebogamma J. Clin. Immunol. 2007 27 6 628 -633
Berger M. and Pinciaro P.H. Flebogamma 5% Investigators. Safety, efficacy, and pharamacokinetics of Flebogamma 5% for replacement therapy in primary immune deficiency J. Clin. Immunol. 2004 24 4 389 -396
Centers for Disease Control and Prevention. 2013. [Online]. FastStats. Available from http://www.cdc.gov/Nchs/fastats/ [accessed 13 January 2014].
Cohn E.J., Strong L.E., Hughes W.L., Mulford D.J., Ashworth J.N., Melin M., and Taylor H.L. Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids J. Am. Chem. Soc. 1946 68 3 459 -475
Eibl M.M. History of immunoglobulin replacement Immunol. Allergy Clin. North America. 2008 28 4 737 -764 Editors: Chaim M Roifman, Rafeul Alam
Geha R. and Notarangelo L. The International Union of Immunological Societies (IUIS) Primary Immunodeficiency Disease (PID) Classification Committee J. Allergy Clin. Immunol. 2007 120 4 776 -794
Guidelines for IVIG replacement. 2014. Canadian Immunodeficiency Society. [Online]. Available from http://immunodeficiency.ca/.
Hooper J. Intravenous immunoglobulin evolution of commercial IVIG preparations Immunol. Allergy Clin. North America. 2008 28 765 -768 Editors: Chaim M. Roifman, Rafeul Alam
Melin J.L., Oncley M., and Richert D.A. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma J. Am. Chem. Soc. 1949 71 2 541 -550
Official Disability Guidelines. 2013. [Online]. Available from http://www.disabilitydurations.com/pr_repmdc.html [accessed 13 January 2014].
Organ J.S., Grossman W.J., and Navickis R.J. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies Clin. Immunol. 2010 137 1 21 -30
Roifman C.M. and Gelfand E.W. Replacement therapy with high dose intravenous gammaglobulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia Pediat. Inf. Dis. J. 1988 7 S92 -S96
Roifman C.M., Levison H., and Gelfand E.W. High dose verses low-dose intravenous immunoglobulin in hypogammaglobinemia and chronic lung disease Lancet. 1987 1 8541 1075 -1077
Roifman C.M., Schroeder H., Berger M., Sorensen R., Ballow M., Buckley R.H., Gewurz A., Korenblat P., Sussman G., and Lemm G. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV –SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial Int. Immunopharmacol. 2003 3 9 1325 -1333
Stein M.R., Nelson R.P., Church J.A., Wasserman R.L., Borte M., Vermylen C., and Bichler J. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiency J. Clin. Immunol. 2009 29 1 137 -144
US FDA. 2012. Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immuno-deficiency. [Online]. Available from http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm072130.htm.
Wasserman R., Church J., and Stein M. Safety, efficacy, and pharmacokinetics of new liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency J. Clin. Immunol. 2012 32 4 663 -669
Information & Authors
Information
Published In
LymphoSign Journal
Volume 2 • Number 1 • March 2015
Pages: 21 - 29
History
Received: 8 August 2014
Accepted: 20 August 2014
Accepted manuscript online: 29 October 2014
Version of record online: 29 October 2014
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
Mark R. Stein, Richard L. Wasserman, James Moy, William Lumry, Eyal Grunebaum, Agnes Nemet, Chaim M. Roifman, and Gordon Sussman. 2015. Efficacy, safety, and tolerability of IVIG-SN in patients with primary immunodeficiency. LymphoSign Journal.
2(1): 21-29. https://doi.org/10.14785/lpsn-2014-0009
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
